Summit Therapeutics (LON:SUMM) Shares Pass Below 200-Day Moving Average of $24.22

Summit Therapeutics PLC (LON:SUMM)’s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $24.22 and traded as low as $21.60. Summit Therapeutics shares last traded at $24.00, with a volume of 135,389 shares traded.

The stock’s 50-day moving average price is GBX 22.59 and its two-hundred day moving average price is GBX 24.22.

About Summit Therapeutics (LON:SUMM)

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

See Also: Fundamental Analysis and Choosing Stocks

Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with's FREE daily email newsletter.